Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications
Source: SeekingAlpha
2025-11-24 15:35:46 ET
The last time I wrote an article on Tonix Pharmaceuticals Holding Corp. ( TNXP ), it was in a Seeking Alpha article entitled "Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years." With respect to this article, I noted that the company was gearing up to have a review by the FDA on whether or not it would receive U.S. marketing approval of the first approved drug to treat these particular patients in over 15 years....
Read the full article on Seeking Alpha
For further details see:
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications
Tonix Pharmaceuticals Holding Corp.
NASDAQ: TNXP
TNXP Trading
1.35% G/L:
$13.54 Last:
257,574 Volume:
$13.67 Open:
TNXP Latest News
March 13, 2026 09:25:00 am
BioMedNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4 and Full-Year 2025 Results, Highlights Launch of TONMYA(TM)
March 13, 2026 08:35:00 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 12, 2026 05:30:00 pm
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 10, 2026 10:21:44 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
TNXP Stock Data
$197,447,991
12,051,314
0.01%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Berkeley Heights
